Please assess the completion status of the following clinical trial:

Trial Title: Mometasone Furoate Nasal Spray for Treatment of Nasal Polyposis After Surgery (Study P03218)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* At least 18 years of age~* Bilateral nasal polyps~* Fulfill criteria for polypectomy (be indicated for surgical - FESS - treatment)~Exclusion Criteria:~* Polypectomy within the last 6 months~* Unhealed nasal surgery/trauma~* \>5 previous polypectomies~* Female of childbearing age who is pregnant, lactating, or not using active contraceptive methods~* Nasal infection~* Pulmonary tuberculosis~* Cystic fibrosis, glaucoma, clinically significant cardiovascular, pulmonary, renal, hepatic, metabolic, hematological, or neurological disease~* Immunocompromised~* Rhinitis medicamentosa (rebound congestion following misuse of nasal decongestants)~* Known hereditary mucociliary dysfunction~* Significant nasal structure abnormalities~* Asthmatic attack within the past 30 days~* Asthmatic patients requiring \>1000 mcg beclomethasone or equivalent~* Asthmatic patients not stable on corticosteroid therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mometasone Furoate Nasal Spray (MFNS) (Type: EXPERIMENTAL): MFNS 200 mcg (2 sprays of 50 mcg in each nostril) once daily in the morning
- Placebo (Type: PLACEBO_COMPARATOR): Placebo nasal spray (2 sprays of 50 mcg in each nostril) once daily in the morning

Based on this trial design, predict the completion outcome and termination type (if applicable).